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Abstract
The pathogenesis of Stevens Johnson Syndrome (SJS) remains obscure but it has been associated 
with various infectious agents, including members of the Herpes virus family. We present the first 
report of high level human herpesvirus-6 (HHV-6) viremia at the onset of SJS suggesting a 
possible new association. This finding supports the need for further investigation into the possible 
relationship between HHV-6 and SJS which may illuminate the pathogenesis of SJS and bring us 
closer to achieving enhanced prevention and treatment of this rare disease.
Keywords
Human Herpesvirus-6; HHV-6; Stevens-Johnson Syndrome; Herpes Viruses
Introduction
Stevens-Johnson Syndrome (SJS) is a rare, idiopathic and poorly understood 
immunologically mediated muco-cutaneous process that is part of a continuum with bullous 
Erythema Multiforme (EM) and Toxic Epidermal Necrolysis Syndrome (TEN)(1) although 
EM remains somewhat distinct from SJS/TENS based on a much stronger association with 
infectious inciting agents. The pathogenesis of SJS is thought to be initiated by an immune 
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response to an antigenic complex formed by drug metabolites or microorganisms. Genetic 
susceptibility has also been implicated with an increased incidence in persons with the HLA-
B12 allele (2). It has been associated with numerous drugs and infectious agents, including 
members of the Herpes virus family such as herpes simplex virus (HSV), cytomegalovirus 
(CMV) and varicella-zoster virus (VZV) (3-6). Erythema multiforme is strongly associated 
with HSV types I and II, with HSV encoded proteins identified in affected epidermis and 
HSV DNA detected in target lesions (7-9).
Human herpesvirus 6 (HHV-6) was first identified in 1986 and quickly reported as the 
etiology of childhood roseola infantum (Sixth disease, exanthum subitum) (10-14). Like 
other herpes viruses, HHV-6 remains latent in host cells after primary infection but can 
reactivate when the immune system is suppressed. In recent years HHV-6 has been 
recognized as an emerging pathogen associated with pneumonitis and encephalitis following 
stem-cell transplantation (15-17) and may be associated with drug-induced hypersensitivity 
syndrome (18). Other novel associations continue to be explored (19-21). In this report, we 
describe two immunocompetent patients with SJS associated with high level HHV-6 variant 
B viremia at onset of clinical presentation. Given its ubiquitous nature, HHV-6 may account 
for a proportion of idiopathic cases of SJS.
Case 1
An 18-year old female with a history of recurrent oral and genital HSV outbreaks presented 
with fever, malaise and myalgias, and subsequently developed 60% total body surface area 
involvement with target lesions, extensive erythematous plaques, bullae involving her face, 
neck, arms, chest, abdomen and proximal extremities as well as epithelial defects and 
pseudomembrane involvement of both conjunctivae. She had extensive orolabial and genital 
mucosal surface denudement and complete epidermal detachment of at least 10% of the skin 
surface of her chest, abdomen, back and face consistent with SJS/TENS (Toxic Epidermal 
Necrolysis Syndrome) based on standard classification (1). Her long-standing medications 
included valacyclovir, promethazine, synthroid, belladonna and orthotricycline. She had not 
taken any newly prescribed medications. Skin biopsy demonstrated vacuolar interface 
dermatitis with a few apoptotic keratinocytes and focal sub-epidermal cleft formation 
consistent with erythema multiforme or early Stevens-Johnson Syndrome. There was no 
viral cytopathic effect noted. Corticosteroids were not administered.
Diagnostic studies included negative urine, blood, and genital tract bacterial cultures, anti-
streptococcal antibodies, Mycoplasma serologies, HIV ELISA and PCR, cytomegalovirus 
(CMV) and Epstein-Barr virus (EBV) plasma PCR tests, and monospot test. HSV type 1 and 
2 PCR tests from genital tract and inner thigh erosion samples were negative. However, 
HHV-6 plasma PCR showed high-level viremia (ViraCor laboratories) 115,000 DNA 
copies/mL (plasma sample obtained prior to first IVIG administration). Genotyping by real-
time PCR identified HHV-6 variant B. Initial serologies (obtained after the initiation of 
intravenous immunoglobulin) showed an IgG of 1:320 and IgM <1:20 (Focus Diagnostics). 
Repeat serologies at 4 weeks reported IgG 1:640 and IgM<1:20. Surprisingly, she continued 
to be viremic at weeks 2, 4 and 8 with values of 19,100 copies/mL, 18,300 copies/mL and 
20,400 copies/mL respectively. At week 14, HHV-6 level had dropped to 2,700 DNA 
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copies/mL and IgG was 1:10 and IgM<1:20. Sequential EBV and CMV plasma DNA PCR 
testing remained negative.
Case 2
A 64-year old woman presented with five days of progressive sore throat, eye irritation and 
malaise and developed target lesions on a background of symmetric diffuse (approximately 
80% total body surface area) erythematous papules and confluent erythema that progressed 
to extensive epidermal detachment (approximately 50% body surface area) as well as 
mucosal erosions involving her conjunctiva and oropharynx. Punch biopsy confirmed 
vacuolar interface and sub-epidermal vesicular dermatitis with focal full thickness epidermal 
necrosis consistent with SJS (see figure). Approximately one month prior to this she was 
treated for a flare of gout with a two-week course of prednisone and allopurinol, a drug 
associated with SJS/TEN. Long-standing medications included hydrochlorothiazide, 
dehydroepiandrosterone, glucosamine, aspirin, and ezetimibe/simvastatin. Corticosteroids 
and intravenous immunoglobulin were not administered.
Initial diagnostic evaluation included negative blood and urine cultures, rapid influenza A/B 
antigen detection, rapid group A Streptococcus antigen detection, anti-streptococcal 
antibodies, EBV and CMV plasma PCR tests. Initial HHV-6 qualitative plasma PCR was 
negative on hospital day #2 in the setting of extensive fluid resuscitation due to insensible 
losses and hypotension, however quantitative testing on hospital day #6 demonstrated 1,500 
DNA copies/mL and by day #8 was 131,000 DNA copies/mL. Follow up HHV-6 viral load 
on hospital day #21 was 400 copies/mL. A lip erosion tested negative for HSV 1/2 by PCR, 
but tested positive for HHV-6 by PCR. Genotype testing confirmed HHV-6 variant B. Initial 
serologies showed HHV-6 IgG 1:640 and IgM <1:20. Convalescent serologies confirmed 
HHV-6 IgG 1:1280 and IgM <1:20. Sequential EBV and CMV plasma PCR tests remained 
negative.
In both patients, baseline serology testing for EBV and CMV were consistent with previous 
exposure and latency (+EBV viral capsid IgG, +CMV IgG) yet serial plasma PCR testing 
for reactivation of these other herpes viruses remained negative. The decision was made to 
withhold anti-viral therapy targeted at HHV-6 based on the unclear significance of this 
association and concern about added medication toxicity. Both patients survived but with 
substantial morbidity. In Case #1, the patient suffered corneal scarring with permanent 
blindness, oropharyngeal stricture and vaginolabial fusion; in Case #2, the patient had a 
prolonged hospitalization complicated by pseudomembranous conjunctivitis, pseudomonal 
pneumonia and multi-system organ failure. She was discharged with tracheostomy and 
feeding tube in place and continues to require hemodialysis.
Discussion
The ability of herpes viruses to lay dormant in host tissue following primary infection 
requires a functioning immune system to prevent reactivation. When there is a disruption or 
alteration in cell-mediated immunity, either because of the use of immunosuppressive 
agents, aging, alteration in cytokine expression (sepsis, burn injury, drug or allergic 
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reaction) or development of an immunosuppressive disorder (e.g., HIV/AIDS, malignancy), 
herpes viruses can replicate and cause an array of medical conditions (22). The relatively 
recent availability of nucleic acid amplification testing has identified many new conditions 
associated with herpes viruses.
In this report, we identified high level HHV-6 viremia temporally associated with the onset 
of SJS, a condition primarily associated with medications but also with herpes family 
viruses and other infectious agents. In Case #1, it is unclear if this represented primary or 
reactivated infection. The patient was younger, had no clear medication precipitant, and her 
HHV-6 viral load remained high for several weeks which may favor primary infection 
(serologies were confounded by the administration of IVIG; the IVIG administered to the 
patient was not tested for the presence of HHV-6 viral particles by PCR or culture, however 
standard manufacturing processes for IVIG incorporate rigorous viral elimination 
procedures [23]). However, reactivation still remains more likely based on sero-
epidemiologic data supporting greater than 90% sero-prevalence of HHV-6 by the age of 2 
(24). A third possibility is congenital chromosomally integrated HHV-6 which can occur in 
about 1% of the population and represents HHV-6 DNA fragments in every nucleated cell. 
While the decline in her viral load over time and the use of acellular (plasma) testing make 
this unlikely, specific testing for chromosomal integration using whole blood or hair follicles 
was not performed (25-26). In Case #2, serologic data supports reactivation disease. She had 
received allopurinol as well as a course of steroids prior to her illness which could have 
precipitated reactivation of HHV-6. Of interest, her lip erosion was positive for HHV-6 by 
PCR, however HHV-6 is commonly shed in saliva and could have contaminated the lesion. 
No viral cytopathic changes were visualized on skin biopsy in both cases but HHV-6 
DNA/RNA testing and protein expression (gp116/54/64) by routine immunohistochemistry 
described by Fotheringham (27) was not performed. Approximately 10 subsequent patients 
with SJS/TEN at our institution, including pediatric patients (looking for an association with 
primary HHV-6 infection), have tested negative for HHV-6 viremia using the same 
diagnostic methods, suggesting HHV-6 as a rare etiology of SJS.
While these two patients presented with high level HHV-6 type B viremia, a causal role for 
HHV-6 in the development SJS cannot be explained without further investigation. Detection 
of HHV-6 viremia in non-immunocompromised patients with acute illness was described in 
one study of patients with multi-system organ failure in which 54% of patients had 
detectable serum HHV-6 DNA by polymerase chain reaction but quantification of viral load 
was not performed and HHV-6 genotype was not reported (28). A subsequent study of 
critically ill patients found a 53% rate of HHV-6 viremia at time of admission to an 
intensive care unit but the nucleic amplification technique utilized in that study included 
peripheral blood leukocytes which can be complicated by chromosomally integrated HHV-6 
DNA (29). In that study, all but one case were typed as HHV-6 variant A (30). A recent 
report of low grade HHV-6 viremia in association with zonisamide related TEN also utilized 
whole blood testing which may be confounded by amplification of latent HHV-6 in 
peripheral monocytes, and in that case HHV-6 DNA was not found early in the disease 
course but was documented at day 22 of hospitalization. CMV and EBV reactivation were 
not reported to look for evidence of other herpes virus reactivation (31).
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A possible role for HHV-6 in the pathogenesis of dermatologic conditions has previously 
been explored. In a study of drug induced hypersensitivity syndrome, Tohyama and 
colleagues showed that anti-HHV-6 IgG titers increased in 62% of patients and HHV-6 
viremia was detected in 18% of patients (range 120-2,400,000 copies/mL) between 10-27 
days after the onset of symptoms and was associated with more severe organ involvement, 
prolonged illness including flaring of fever and hepatitis, and mortality in comparison to 
those patients without evidence of HHV-6 reactivation (18). The authors postulate that 
potent drug-reactive T cells act similarly to alloreactive T cells following organ 
transplantation and may drive HHV-6 reactivation. Interestingly, they also report no cases of 
HHV-6 reactivation among 10 patients diagnosed with SJS or TEN in their discussion and a 
recent investigation in China into the etiology of SJS found no HHV-6 reactivation among 
16 patients surveyed using DNA PCR (32). Therefore, we report the first two cases of SJS 
associated with high level HHV-6 viremia at onset of disease. Our report is limited based on 
data from 2 distinct patients, one of whom had allopurinol as a likely drug precipitant (case 
2) and one of whom had IVIG administration (case 1) precluding conclusive serologic 
interpretation. However, the demonstration of high level viremia determined by quantitative 
real time PCR testing in the first week of hospitalization is compelling evidence for active 
HHV6 replication. Whether this replication is a bystander and marker of immune 
dysregulation or has a pathogenic role in these dermatologic conditions remains undefined 
but merits further investigation.
SJS is a serious and potentially lethal disease. There is currently no way to predict who may 
be affected and no means of prevention. Further research into the association of HHV-6 and 
SJS may illuminate its pathogenesis, help define the cascade of immunologic events induced 
by drug and viral antigens, and bring us closer to achieving enhanced prevention and 
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Vacuolar alteration of the dermal epidermal interface associated with scattered apoptotic 
keratinocytes is present on the left side of the image with progression to subepidermal cleft 
formation and full thickness epidermal necrosis on the right side of the image (original 
magnification × 200).
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